Sansure Biotech

Sansure Biotech EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sansure Biotech (688289.SS) as of Oct 30, 2026 is 202.43 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 409.82 M CNY — a change of -50.61% (lower).

EBITDA

202.43 MCNY

YoY

-50.61%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sansure Biotech is 2025 202.43 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sansure Biotech was 2024 409.82 M CNY. It decreases by -50.61% lower compared to the previous year.

The Sansure Biotech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
28.10 M CNY
Jan 1, 2019
65.02 M CNY
Jan 1, 2020
3.11 B CNY
Jan 1, 2021
2.67 B CNY
Jan 1, 2022
2.41 B CNY
Jan 1, 2023
522.64 M CNY
Jan 1, 2024
409.82 M CNY
Jan 1, 2025
202.43 M CNY
The Sansure Biotech EBITDA history
YEAREBITDAYoY
202.43 MCNY-50.61%
409.82 MCNY-21.59%
522.64 MCNY-78.35%
2.41 BCNY-9.47%
2.67 BCNY-14.23%
3.11 BCNY+4,681.76%
65.02 MCNY+131.35%
28.10 MCNY-333.61%
-12.03 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sansure Biotech Stock analysis

What does Sansure Biotech do? Sansure Biotech, Inc. generates revenue through the research, development, production, and sales of diagnostic reagents and instruments. Its diagnostic reagent portfolio includes the viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series, and nucleic acid blood screening series. The company also offers instrument products such as the automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction monitoring and analysis software. The firm extends its business model by providing related inspection services, specifically medical inspection and scientific research services, which are delivered to medical institutions. This combination of product sales and service provision allows Sansure Biotech, Inc. to serve the healthcare and research sectors with its comprehensive diagnostic solutions. Sansure Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sansure Biotech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sansure Biotech is 202.43 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sansure Biotech changed from 409.82 M CNY to 202.43 M CNY, representing a -50.61% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sansure Biotech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sansure Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Sansure Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sansure Biotech